Trial Profile
Protocol EC-FV-02: A Phase II Study of EC145 in Patients With Advanced Ovarian and Endometrial Cancers.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Technetium Tc99m etarfolatide (Primary) ; Vintafolide (Primary)
- Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Biomarker; Diagnostic use; Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 01 Mar 2013 Results have been presented at the 2013 AACR-SNMMI Joint Conference on State-of-the-Art Molecular Imaging in Cancer Biology and Therapy according to an Endocyte media release. Results were also summarised in the media release.
- 13 Apr 2012 Actual patient number is 49 according to ClinicalTrials.gov.
- 13 Apr 2012 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.